$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000162828019006594 Filed on May 10, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$53.98M	$36.66M	$16.69M
YoY Change	178.48%	119.6%
Cost Of Revenue	$16.83M	$13.54M	$9.250M
YoY Change	68.98%	46.38%
Gross Profit	$37.14M	$23.12M	$7.440M
YoY Change	294.27%	210.75%
Gross Profit Margin	68.81%	63.07%	44.57%
Selling, General & Admin	$32.88M	$30.47M	$17.83M
YoY Change	59.82%	70.87%
% of Gross Profit	88.52%	131.78%	239.66%
Research & Development	$19.53M	$16.32M	$8.255M
YoY Change	69.05%	97.65%
% of Gross Profit	52.59%	70.57%	110.95%
Depreciation & Amortization	$2.200M	$2.354M	$1.395M
YoY Change	69.23%	68.75%
% of Gross Profit	5.92%	10.18%	18.75%
Operating Expenses	$52.41M	$46.78M	$26.09M
YoY Change	63.14%	79.35%
Operating Profit	-$15.27M	-$23.66M	-$18.65M
YoY Change	-32.75%	26.91%
Interest Expense	$287.0K	$293.0K	$331.0K
YoY Change	-9.46%	-11.48%
% of Operating Profit
Other Income/Expense, Net	-$51.00K	$147.0K	$4.149M
YoY Change	-112.91%	-96.46%
Pretax Income	-$12.51M	-$21.33M	-$13.84M
YoY Change	-42.19%	54.04%
Income Tax	-$1.207M	$26.00K	$0.00
% Of Pretax Income
Net Earnings	-$11.30M	-$21.35M	-$13.84M
YoY Change	-47.78%	54.23%
Net Earnings / Revenue	-20.94%	-58.25%	-82.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$130.3K	-$303.1K	-$165.6K
COMMON SHARES
Basic Shares Outstanding	87.11M shares	85.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$545.6M	$466.9M
YoY Change	107.14%
Cash & Equivalents	$174.7M	$153.8M	$75.77M
Short-Term Investments	$371.0M	$313.1M
Other Short-Term Assets	$4.100M	$6.200M
YoY Change	36.67%
Inventory	$14.18M	$10.26M
Prepaid Expenses
Receivables	$40.36M	$40.60M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$604.2M	$512.3M
YoY Change	112.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.81M	$30.58M
YoY Change	18.81%
Goodwill
YoY Change
Intangibles	$8.987M
YoY Change
Long-Term Investments	$277.3M	$25.90M
YoY Change	633.6%
Other Assets	$3.159M	$2.862M
YoY Change	-73.89%
Total Long-Term Assets	$335.7M	$66.92M
YoY Change	324.99%
TOTAL ASSETS
Total Short-Term Assets	$604.2M	$512.3M
Total Long-Term Assets	$335.7M	$66.92M
Total Assets	$940.0M	$579.2M
YoY Change	159.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.70M	$7.163M
YoY Change	82.56%
Accrued Expenses	$11.09M	$9.137M
YoY Change	-31.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K
YoY Change	0.0%
Total Short-Term Liabilities	$57.05M	$48.19M
YoY Change	91.44%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$100.0K
YoY Change	-50.0%
Other Long-Term Liabilities	$1.303M	$150.0K
YoY Change	-91.37%
Total Long-Term Liabilities	$1.303M	$150.0K
YoY Change	-91.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.05M	$48.19M
Total Long-Term Liabilities	$1.303M	$150.0K
Total Liabilities	$77.72M	$64.54M
YoY Change	-9.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$314.8M	-$275.9M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$815.5M	$468.1M	$296.8M
YoY Change
Total Liabilities & Shareholders Equity	$940.0M	$579.2M
YoY Change	159.09%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$11.30M	-$21.35M	-$13.84M
YoY Change	-47.78%	54.23%
Depreciation, Depletion And Amortization	$2.200M	$2.354M	$1.395M
YoY Change	69.23%	68.75%
Cash From Operating Activities	-$13.84M	-$4.303M	-$6.559M
YoY Change	-18.78%	-34.4%
INVESTING ACTIVITIES
Capital Expenditures	-$3.040M	$2.705M	$4.021M
YoY Change	-58.58%	-32.73%
Acquisitions
YoY Change
Other Investing Activities	-$317.5M	$18.03M	$12.49M
YoY Change	-1764.81%	44.36%
Cash From Investing Activities	-$320.5M	$15.33M	$8.470M
YoY Change	-2832.57%	80.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	355.1M	$2.288M	$1.267M
YoY Change	771.77%	80.58%
NET CHANGE
Cash From Operating Activities	-13.84M	-$4.303M	-$6.559M
Cash From Investing Activities	-320.5M	$15.33M	$8.470M
Cash From Financing Activities	355.1M	$2.288M	$1.267M
Net Change In Cash	20.70M	$13.25M	$3.178M
YoY Change	-41.56%	316.77%
FREE CASH FLOW
Cash From Operating Activities	-$13.84M	-$4.303M	-$6.559M
Capital Expenditures	-$3.040M	$2.705M	$4.021M
Free Cash Flow	-$10.80M	-$7.008M	-$10.58M
YoY Change	11.34%	-33.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87112669	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Guardant Health, Inc.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q1	dei	Trading Symbol TradingSymbol	GH
CY2018Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	343000	USD
CY2019Q1	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	137000	USD
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
CY2018Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7338000	USD
CY2019Q1	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7120000	USD
CY2018Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	381776000	USD
CY2019Q1	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	349078000	USD
CY2019Q1	gh	Contractual Obligation Future Minimum Payments Interest Includedin Payments ContractualObligationFutureMinimumPaymentsInterestIncludedinPayments	5711000	USD
CY2019Q1	gh	Contractual Obligation Future Minimum Payments Present Valueof Net Minimum Payments ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments	7120000	USD
CY2018Q1	gh	Costof Development Services CostofDevelopmentServices	1208000	USD
CY2019Q1	gh	Costof Development Services CostofDevelopmentServices	2512000	USD
CY2018Q1	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	8045000	USD
CY2019Q1	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	11023000	USD
CY2018Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	381858000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1933000	USD
CY2018Q1	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	-206000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-83000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	333000	USD
CY2019Q1	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	348675000	USD
CY2018Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	814000	USD
CY2019Q1	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	2400000	USD
CY2018Q1	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	3351000	USD
CY2019Q1	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	490000	USD
CY2018Q1	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	3000	USD
CY2019Q1	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	0	USD
CY2019Q1	gh	Numberof Parties With Patent License Agreement NumberofPartiesWithPatentLicenseAgreement	4	party
CY2017Q1	gh	Payment In Connection Witha License Agreement PaymentInConnectionWithaLicenseAgreement	9700000	USD
CY2018Q1	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
CY2019Q1	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	73000	USD
CY2018Q1	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	2501000	USD
CY2019Q1	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	7818000	USD
CY2018Q1	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	14191000	USD
CY2019Q1	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	28837000	USD
CY2018Q1	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.01
CY2019Q1	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2018Q4	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	508847	shares
CY2019Q1	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	812	shares
CY2019Q1	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	18370	shares
CY2018Q1	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	4000	USD
CY2019Q1	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	56000	USD
CY2019Q1	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	144000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10642000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7163000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35690000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28989000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40597000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	78000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	553000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1470000	USD
CY2019Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1410000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7081000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9137000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1791000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1988000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	707000	USD
CY2019Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	853000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16634000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16303000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764033000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	771009000	USD
CY2019Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1277000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3183000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1277000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3182000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	189000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	243000	USD
CY2018Q1	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	64000	USD
CY2019Q1	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	30000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	66061000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7681000	shares
CY2018Q4	us-gaap	Assets Assets	587403000	USD
CY2019Q1	us-gaap	Assets Assets	579171000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	468991000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	512255000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	481000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	317000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	97000	USD
CY2019Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	96000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	119000	USD
CY2019Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	100000	USD
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	504000	USD
CY2019Q1	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	504000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	251000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	36000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	108000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	55000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	196000	USD
CY2019Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	107000	USD
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	294000	USD
CY2019Q1	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	324000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140544000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153790000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72596000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75774000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153789000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3178000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13245000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12067162	shares
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11719565	shares
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85832454	shares
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14142000	USD
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86098474	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85832454	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86098474	shares
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25635000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14142000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20935000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16100000	USD
CY2019Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17100000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7000000	USD
CY2019Q1	us-gaap	Contractual Obligation ContractualObligation	12831000	USD
CY2019Q1	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	5609000	USD
CY2019Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	1683000	USD
CY2019Q1	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1683000	USD
CY2019Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1402000	USD
CY2019Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1402000	USD
CY2019Q1	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	1052000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	35339000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	60319000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12986000	USD
CY2019Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	14683000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7844000	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8975000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16138000	USD
CY2019Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	17113000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	1200000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	2100000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1395000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2354000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.16
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-69000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M21D
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M27D
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17500000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	16600000	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y0M0D
CY2019Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y9M0D
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7600000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7557000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6519000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12661000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13844000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21325000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1697000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-321000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1120000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-255000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1989000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	833000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1312000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	947000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-48000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	331000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	293000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	30000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	293000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46944000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48192000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	9136000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	10256000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	278417000	USD
CY2019Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	313069000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2610000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-623000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11608000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1108000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2308000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-621000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-1131000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1491000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	975000	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-608000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	985000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2485000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	62451000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	64537000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587403000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	579171000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	77563000	USD
CY2019Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	25916000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1267000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2288000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8470000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15329000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6559000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4303000	USD
CY2018Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4700000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-298000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	45966000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4021000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	4700000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13844000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26051000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18647000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23664000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	62617000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3693000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9023000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	8388000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8161000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7276000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26076000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1956000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2349000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2046000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2862000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-69000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-298000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	416000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	485000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	206000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4149000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	147000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19634000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2705000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5204000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6151000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	32125000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	64000000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1310000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	538000	USD
CY2018Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2019Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1933000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-13844000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46884000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1103000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-21351000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47637000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31003000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30581000	USD
CY2019Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4700000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	41800000	USD
CY2019Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	46500000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	47000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	21000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8255000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16316000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280799000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303209000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275892000	USD
CY2018Q1	us-gaap	Revenues Revenues	16692000	USD
CY2019Q1	us-gaap	Revenues Revenues	36655000	USD
CY2018Q1	us-gaap	Royalty Expense RoyaltyExpense	172000	USD
CY2019Q1	us-gaap	Royalty Expense RoyaltyExpense	633000	USD
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11312000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17807000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1277000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3182000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.667
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3556507	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3436451	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.61
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	82389	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	18370	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.77
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.90
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	250495000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	531281000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7588405	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7378068	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.58
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3361540	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.49
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.77
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	41.25
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M21D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	245680000	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M17D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M6D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y0M14D
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	146318	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	538000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	308606000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	296848000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	468134000	USD
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.7378
CY2019Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	3900000	USD
CY2019Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4900000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	48300000	USD
CY2019Q1	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	47000000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	1200000	USD
CY2019Q1	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	942000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11920000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85935000	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
R39.htm	Edgar Link	pending
0001628280-19-006594-index-headers.html	Edgar Link	pending
0001628280-19-006594-index.html	Edgar Link	pending
0001628280-19-006594.txt	Edgar Link	pending
0001628280-19-006594-xbrl.zip	Edgar Link	pending
a10-qexhibitghlanmansigned.htm	Edgar Link	pending
a10-qexhibitghleenasignedo.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-03312019x10q.htm	Edgar Link	pending
gh-0331x2019x10qxexhibit311.htm	Edgar Link	pending
gh-0331x2019x10qxexhibit312.htm	Edgar Link	pending
gh-0331x2019x10qxexhibit321.htm	Edgar Link	pending
gh-0331x2019x10qxexhibit322.htm	Edgar Link	pending
gh-20190331.xml	Edgar Link	completed
gh-20190331.xsd	Edgar Link	pending
gh-20190331_cal.xml	Edgar Link	unprocessable
gh-20190331_def.xml	Edgar Link	unprocessable
gh-20190331_lab.xml	Edgar Link	unprocessable
gh-20190331_pre.xml	Edgar Link	unprocessable
guardanthealth-directorcom.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2019 Q2 Form 10-Q Financial Statement

#000162828019006594 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2019 Q2 Form 10-Q Financial Statement

#000162828019006594 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh